Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? ProShares UltraPro Short QQQ ETF trades at $37.19 (market cap $2.13B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.5× ProShares UltraPro Short QQQ ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SQQQ | SYRE | |
|---|---|---|
Market Cap | $2.13B | $7.52B |
Volume | 37,167,173 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $108.92 |
52-Week Low | $31.83 | $22.18 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.98, up 1.04% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, its performance is directly tied to declines in the Nasdaq-100 index. Recent news highlights its use as a hedging tool against tech sector weakness, with articles discussing its potential benefits amid concerns over the AI-fueled tech rally.
The outlook for SQQQ is inherently tied to market sentiment toward the Nasdaq-100. It presents a high-risk, tactical opportunity for investors seeking to profit from or hedge against a downturn in major technology stocks. Key risks include the daily reset mechanism of leveraged ETFs, which can lead to decay in volatile markets, and the potential for rapid losses if the tech rally resumes.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
